September 20, 2023 11:26 AM EDT
News Briefing

Atara to file T cell im­munother­a­py in the US in 2024; Rayze­Bio clos­es $358M IPO

Lei Lei Wu

News Reporter

Kyle LaHucik

Senior Reporter

Ayisha Sharma

News Reporter

Atara Bio­ther­a­peu­tics said Tues­day that it plans to sub­mit its T cell im­munother­a­py for ap­proval in the US next year. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times